What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near

MeiraGTx Chief Scientific Officer Stuart Naylor sold 27,659 shares (4% of holdings) for $409,000 on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025. The sale appears routine following an 89% one-year stock surge and likely reflects portfolio diversification rather than lack of confidence. The company remains well-positioned with a Lilly collaboration worth $75M upfront plus $400M+ in milestones, FDA Breakthrough Therapy Designation for its dry-mouth therapy, and plans to file for approval on two wholly-owned therapies within two years.